{"entity":{"id":"asp2998","kind":"drug","name":"ASP2998","aka":[],"tldr":"An experimental drug that uses an antibody to deliver a cancer-killing drug and an immune activator to cells carrying TROP2. An early human study is recruiting; benefit and safety are still being tested.","summary":"ASP2998 is Astellas's TROP2-targeted immunostimulatory dual-payload ADC, discovered through collaborative research with Sutro Biopharma. The phase 1b/2 first-in-human study NCT07287995 evaluates monotherapy and tumor-specific combinations. The registry, last updated 2 September 2026 and checked 6 October, lists recruiting status, an actual start on 5 February 2026 and estimated enrollment of 428. The earlier ASCO 2026 trial-in-progress abstract planned 196 participants; it is not an efficacy readout. No results are posted in the registry. Astellas lists the program in phase 1; the registered phase 1/2 design does not establish completion of phase 1 or demonstrated efficacy.","status":"phase-1","asOf":"2026-10-06","links":[{"label":"Astellas pipeline: ASP2998 and Sutro collaboration","url":"https://www.astellas.com/en/science/research-and-development/pipeline"},{"label":"Astellas FY2025 pipeline: phase 1 ASP2998","url":"https://www.astellas.com/content/dam/astellas-com/global/en/confidential-documents/financial-results/4q2025_sup_en.pdf"},{"label":"Astellas FY2025 results: TOP1 inhibitor and STING agonist","url":"https://www.astellas.com/content/dam/astellas-com/global/en/confidential-documents/financial-results/4q2025_pre_en.pdf"},{"label":"ASCO 2026 trial-in-progress abstract TPS2665","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2665"},{"label":"ClinicalTrials.gov NCT07287995","url":"https://clinicaltrials.gov/study/NCT07287995"}],"tags":["pipeline","dual-payload","immunostimulatory"],"related":[],"cancers":[],"sections":[],"technologies":["adc","dual-payload-adc"],"targets":["trop2"],"drugs":[],"companies":["astellas"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07287995"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"code":"ASP2998","modality":"ADC","payload":"Topoisomerase I inhibitor and STING agonist","mechanism":"TROP2-directed antibody carrying a cytotoxic topoisomerase I inhibitor and a STING immune agonist. This is an immunostimulatory dual-payload ADC, rather than two cytotoxic payloads.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/asp2998/","neighbours":{"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"dual-payload-adc","kind":"technology","name":"Dual-payload ADC","route":"/technologies/dual-payload-adc/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"company":[{"id":"astellas","kind":"company","name":"Astellas","route":"/companies/astellas/"}],"trial":[{"id":"nct07287995","kind":"trial","name":"A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors","route":"/trials/nct07287995/"}]}}